论文部分内容阅读
目的探讨依达拉奉与低分子肝素联合治疗进展性卒中的临床效果。方法选取100例患有进展性卒中的患者,将其分为两组,实验组和对照组,每组50人。对照组患者在常规治疗的基础上给予低分子肝素5000 U进行腹部皮下注射,每12 h注射一次,连用14 d。实验组患者在常规治疗和给予低分子肝素注射的同时加用依达拉奉30 mg加入生理盐水100 ml进行静脉滴注,2次/d,连用14 d。对比治疗前后患者的治疗效果、神经功能缺损的程度。结果两组患者在治疗前后临床疗效和神经功能缺损均有改善,实验组的总有效率为89%,对照组总有效率为70.3%,实验组患者改善较对照组更明显。结论依达拉奉联合低分子肝素治疗进展性卒中效果显著,有助于改善神经功能,无明显的不良反应,值得推广使用。
Objective To investigate the clinical efficacy of edaravone combined with low molecular weight heparin in the treatment of advanced stroke. Methods A total of 100 patients with progressive stroke were enrolled and divided into two groups: experimental group and control group, with 50 in each group. Patients in the control group were subcutaneously injected with low molecular weight heparin 5000 U on the basis of routine treatment and injected every 12 hours for 14 days. Patients in the experimental group were given intravenous infusion of low molecular weight heparin and edaravone 30 mg at a dose of 100 ml and saline twice a day for 14 days. Comparison of treatment before and after treatment of patients, the extent of neurological deficits. Results Before and after treatment, the clinical efficacy and neurological deficit were improved in both groups. The total effective rate was 89% in the experimental group and 70.3% in the control group. The improvement in the experimental group was more obvious than that in the control group. Conclusion Edaravone combined with low molecular weight heparin is effective in treating progressive stroke, which can improve neurological function without obvious adverse reactions and is worth promoting.